Supernus to Report Third Quarter 2026 Results on October 29

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) will report its third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026. The Rockville, Maryland-based biopharmaceutical company announced the schedule in a press release dated October 19, 2026.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Following management’s prepared remarks, the call will be open for questions. Participants can access the live webcast through the Events & Presentations section of the company’s Investor Relations website.

Investors may pre-register for the call at any time before the start. Once registration is complete, participants will receive a dial-in number and a personalized conference code. The company advises dialing in 15 minutes prior to the start time to ensure access. A replay of the call will be available on the company’s Investor Relations website at www.supernus.com/investors . The webcast will remain accessible on the company’s website for 60 days following the live event.

Supernus Pharmaceuticals focuses on developing and commercializing products for central nervous system diseases. Its portfolio includes approved treatments for attention-deficit hyperactivity disorder, dyskinesia in Parkinson's disease patients receiving levodopa-based therapy, hypomobility in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing novel product candidates for other CNS disorders.

The press release includes forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include the company’s ability to sustain profitability, raise sufficient capital, implement its corporate strategy, and increase prescriptions and net revenue for its products and those acquired through Sage. Additional factors involve commercialization efforts, future collaborations, clinical trial timing, regulatory approvals, intellectual property protection, manufacturing capabilities, and changes in laws or macroeconomic conditions such as trade disputes and tariffs. Supernus undertakes no obligation to update the information in the release to reflect events after the date of issuance.

Investor inquiries can be directed to Peter Vozzo at ICR Healthcare via email at [email protected] or by phone at (443) 213-0505. General company contact is available through Jack A. Khattar or Timothy C. Dec at (301) 838-2591.